Neisseria meningitidis News and Research RSS Feed - Neisseria meningitidis News and Research

Low dose injections of artificial properdin provides protection against septic diseases in mice

Breakthrough MRC-funded study from University of Leicester shows low dose injections of artificial properdin provides substantial protection against septic diseases in mice [More]
Low dose injections of artificial properdin provide protection against septic diseases

Low dose injections of artificial properdin provide protection against septic diseases

Researchers at the University of Leicester have produced an artificial version of a naturally occurring protein, properdin, which has been found to successfully combat bacterial pneumonia and meningitis when tested in mice. [More]
Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip." [More]
Researchers create an efficient technique to target and repair defective genes

Researchers create an efficient technique to target and repair defective genes

Using human pluripotent stem cells and DNA-cutting protein from meningitis bacteria, researchers from the Morgridge Institute for Research and Northwestern University have created an efficient way to target and repair defective genes. [More]
Researchers discover role of TonB bacterial protein that causes various diseases

Researchers discover role of TonB bacterial protein that causes various diseases

A Kansas State University-led study has discovered the role of a protein in bacteria that cause a wide variety of diseases, including typhoid fever, plague, meningitis and dysentery. The results may lead to new and improved antibiotics for humans and animals. [More]
Common sugar molecule promising target for development of broad-spectrum vaccine

Common sugar molecule promising target for development of broad-spectrum vaccine

Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens. [More]

Neisseria meningitidis causes life threatening meningitis, meningococcal sepsis in humans

"Neisseria meningitidis is an important human pathogen that can cause rapidly progressing, life threatening meningitis and meningococcal sepsis in humans," Professor Jennings said. [More]
CRISPR helps some bacteria evade mammalian immune system

CRISPR helps some bacteria evade mammalian immune system

CRISPR, a system of genes that bacteria use to defend themselves against viruses, has been found to be involved in helping some bacteria evade the mammalian immune system. [More]
Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages. [More]
Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech announces acquisition of Meningitec from Pfizer

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced it has acquired from Pfizer Inc. Meningitec, which is a vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. [More]
New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments urgently needed for bacterial meningitis

New vaccines and drug treatments are urgently needed for bacterial meningitis, a devastating disease which kills or maims around a fifth of people who contract it, according to medical experts writing in a new Series on bacterial meningitis, published in The Lancet. [More]

FDA approves GSK’s MenHibrix to treat meningococcal and Hib diseases

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine]. [More]

FDA approves Menhibrix for vaccination against meningococcal and Hib diseases

The U.S. Food and Drug Administration today approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b. [More]
Routine 4CMenB immunizations effective against meningococcal strains in infants

Routine 4CMenB immunizations effective against meningococcal strains in infants

Administration of routine infant immunizations with a vaccine for serogroup B Neisseria meningitidis, a bacterium that is a cause of serious disease such as sepsis and meningitis, was effective against meningococcal strains and produced minimal interference with the response to the routine vaccinations, according to a study in the February 8 issue of JAMA. [More]
EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

EC extends therapeutic indication for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). [More]
FDA approves Sanofi Pasteur's meningococcal vaccine

FDA approves Sanofi Pasteur's meningococcal vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra, to include a two-dose schedule for infants and children 9 months through 23 months of age. [More]

Avenir team discovers how Neisseria meningitidis disseminates into bloodstream

Although, in the majority of cases, the localized presence of Neisseria meningitidis in the throat has no consequence, it can sometimes lead to meningitis or septicaemia. The seriousness of these two infections is driving researchers from around the world to improve their understanding of the mode of operation of this bacterium, which, once it leaves its favourite location becomes extremely dangerous. [More]
First evidence of human DNA fragment in bacterial genome

First evidence of human DNA fragment in bacterial genome

If a human cell and a bacterial cell met at a speed-dating event, they would never be expected to exchange phone numbers, much less genetic material. In more scientific terms, a direct transfer of DNA has never been recorded from humans to bacteria. [More]

MenAfriVac to help health workers eliminate meningococcal A epidemics

The West African nation of Burkina Faso today became the first country to begin a nationwide campaign to introduce a new meningitis vaccine that promises to rid the entire region of the primary cause of epidemic meningitis. The first vaccine designed specifically for Africa, MenAfriVac is expected to help health workers eliminate meningococcal A epidemics in the 25 countries of the meningitis belt, stretching from Senegal in the west to Ethiopia in the east. [More]
Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Bacterial study confirms TLR2 signaling vital for activating human airway epithelial cells

Researchers from the Boston University School of Medicine (BUSM) have demonstrated that commensal species of the genus Neisseriae are low inducers of human airway epithelial cell responses as compared to the pathogenic species. [More]